AnaptysBio, Inc (ANAB) income statement
ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/30
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026Market cap $2.28BP/E –Yield –
AnaptysBio, Inc income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- 131.7%
- Net margin
- 82.4%
- Return on equity, FY2025
- -24.5%
Financial strength
- Current ratio
- 5.61
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 378.5%
Valuation
- P/E ratio
- –
- Price to sales
- 9.59
- Price to book
- 215.20
- Dividend yield
- –
See a number that looks wrong?